LEAH LabsEngineering living therapies for pets and their people

LEAH Labs - Building Cell Therapies Faster Than Biology

Revolutionizing Medicine Development

LEAH Labs is at the forefront of generative biology, addressing the bottleneck in translating therapeutic proteins from in silico experiments to real-world medicine. Our Bits to Therapies™ platform accelerates the development of cell therapies for cancer, surpassing traditional biological methods.

Key Features

• Bits to Therapies™ Platform: Screens novel protein designs in therapeutic contexts.
• CAR-T Cell Therapy: Genetically reprograms T immune cells to target and destroy cancer.
• Veterinary Partnerships: Collaborates with leading institutions for pre-clinical trials.
• Human and Pet Health: Develops treatments for both human and animal cancers.

Use Cases

• Cancer Treatment: Fast-tracks the development of cell therapies for various cancers.
• Veterinary Medicine: Provides advanced cancer treatments for pets.
• Pre-Clinical Trials: Partners with veterinary institutions for trial enrollments.
• Research and Development: Innovates in the field of generative biology and therapeutic proteins.

Pricing

LEAH Labs offers fully funded pilot efficacy trials, launching in Q3 2024. Our trials are available to licensed veterinarians and their patients under 9 CFR 103.3. Safety and efficacy of our experimental products have not been established with or approved by USDA-CVB.

Teams

LEAH Labs collaborates with top veterinary institutions such as the University of Minnesota, Ohio State University, University of Missouri, and North Carolina State University. Our team is dedicated to advancing CAR-T cell therapy for both human and animal health, supported by investors like Y Combinator and grants from NSF SBIR, NIH SBIR, and others.